方盛製藥(603998.SH):6名董監高減持期屆滿 合計減持6.87萬股
格隆匯 9 月 1日丨方盛製藥(603998.SH)公佈,此次減持時間區間屆滿,2020年3月27日,副總經理劉新合通過集中競價的方式減持3.75萬股,佔公司總股本0.0087%,劉新合此次減持計劃實施完成;2020年5月22日,董事、副總經理陳波通過集中競價的方式減持1.25萬股,佔公司總股本0.0029%,陳波此次減持計劃實施完成;2020年6月16日,副總經理(已辭任)周偉恩通過集中競價的方式堅持1.87萬股,佔公司總股本0.0044%,周偉恩此次減持計劃實施完成;減持計劃期間,董事陳愛春、總經理、董事會祕書肖漢卿、監事會主席方傳龍未減持股份。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.